Fingerprint
Dive into the research topics of 'Erratum: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically